Santhera Pharmaceuticals (Switzerland) Price Patterns
| SANN Stock | CHF 17.06 0.02 0.12% |
Momentum 52
Impartial
Oversold | Overbought |
EPS Estimate Current Year (3.47) | EPS Estimate Next Year (0.05) | Wall Street Target Price 30 | EPS Estimate Current Quarter (0.74) | Quarterly Revenue Growth 0.701 |
Using Santhera Pharmaceuticals hype-based prediction, you can estimate the value of Santhera Pharmaceuticals Holding from the perspective of Santhera Pharmaceuticals response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Santhera Pharmaceuticals to buy its stock at a price that has no basis in reality. In that case, they are not buying Santhera because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Santhera Pharmaceuticals after-hype prediction price | CHF 17.23 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Santhera |
Santhera Pharmaceuticals After-Hype Price Density Analysis
As far as predicting the price of Santhera Pharmaceuticals at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Santhera Pharmaceuticals or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Santhera Pharmaceuticals, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Santhera Pharmaceuticals Estimiated After-Hype Price Volatility
In the context of predicting Santhera Pharmaceuticals' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Santhera Pharmaceuticals' historical news coverage. Santhera Pharmaceuticals' after-hype downside and upside margins for the prediction period are 13.98 and 20.48, respectively. We have considered Santhera Pharmaceuticals' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models compare with traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Santhera Pharmaceuticals is not too volatile at this time. Analysis and calculation of next after-hype price of Santhera Pharmaceuticals is based on 3 months time horizon.
Santhera Pharmaceuticals Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Santhera Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Santhera Pharmaceuticals backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Santhera Pharmaceuticals, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.62 | 3.25 | 0.15 | 0.12 | 2 Events / Month | 1 Events / Month | In a few days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
17.06 | 17.23 | 0.88 |
|
Santhera Pharmaceuticals Hype Timeline
Santhera Pharmaceuticals is at this time traded for 17.06on SIX Swiss Exchange of Switzerland. The entity has historical hype elasticity of 0.15, and average elasticity to hype of competition of 0.12. Santhera is anticipated to increase in value after the next headline, with the price projected to jump to 17.23 or above. The average volatility of media hype impact on the company the price is over 100%. The price increase on the next news is anticipated to be 0.88%, whereas the daily expected return is at this time at 0.62%. The volatility of related hype on Santhera Pharmaceuticals is about 1681.76%, with the expected price after the next announcement by competition of 17.18. The company reported the revenue of 39.12 M. Net Loss for the year was (41.97 M) with profit before overhead, payroll, taxes, and interest of 6.57 M. Assuming the 90 days trading horizon the next anticipated press release will be in a few days. Check out Santhera Pharmaceuticals Basic Forecasting Models to cross-verify your projections.Santhera Pharmaceuticals Related Hype Analysis
Having access to credible news sources related to Santhera Pharmaceuticals' direct competition is more important than ever and may enhance your ability to predict Santhera Pharmaceuticals' future price movements. Getting to know how Santhera Pharmaceuticals' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Santhera Pharmaceuticals may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| MOLN | Molecular Partners AG | 0.02 | 4 per month | 2.78 | 0.05 | 6.16 | (4.33) | 21.26 | |
| ASCN | Ascom Holding AG | 3.00 | 10 per month | 1.62 | 0.16 | 6.44 | (2.86) | 21.33 | |
| ADXN | Addex Therapeutics | (0) | 4 per month | 0.00 | (0.09) | 6.00 | (6.90) | 17.23 | |
| EVE | Evolva Holding SA | 0.00 | 0 per month | 4.19 | (0) | 8.79 | (9.09) | 23.36 | |
| NWRN | Newron Pharmaceuticals SpA | (1.45) | 5 per month | 2.95 | 0.15 | 6.92 | (5.30) | 21.18 | |
| SHLTN | S H L | (0.05) | 8 per month | 6.21 | 0.12 | 12.37 | (9.35) | 92.47 | |
| DOCM | DocMorris AG | (0.07) | 6 per month | 3.25 | 0.03 | 7.96 | (5.59) | 21.23 | |
| CLTN | Coltene Holding AG | 0.10 | 3 per month | 1.78 | 0.15 | 4.27 | (2.64) | 11.91 |
Santhera Pharmaceuticals Additional Predictive Modules
Most predictive techniques to examine Santhera price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Santhera using various technical indicators. When you analyze Santhera charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Santhera Pharmaceuticals Predictive Indicators
The successful prediction of Santhera Pharmaceuticals stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Santhera Pharmaceuticals Holding, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Santhera Pharmaceuticals based on analysis of Santhera Pharmaceuticals hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Santhera Pharmaceuticals's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Santhera Pharmaceuticals's related companies.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Santhera Stock Analysis
When running Santhera Pharmaceuticals' price analysis, check to measure Santhera Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Santhera Pharmaceuticals is operating at the current time. Most of Santhera Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Santhera Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Santhera Pharmaceuticals' price. Additionally, you may evaluate how the addition of Santhera Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.